Loading
Every dated change on the records linked to Localised prostate cancer, very low and low risk, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Clinically significant cancer 38% vs 26%.
Prostate cancer deaths 71 of 347 with surgery against 110 of 348 with watchful waiting (relative risk 0.
A milestone in how this cancer is treated.
Disease progression at 24 months in 28 percent after padeliporfin vascular-targeted photodynamic therapy against 58 percent under active surveillance (adjusted hazard ratio 0.
All-cause mortality 61.
Multiparametric MRI sensitivity 93 percent against 48 percent for transrectal biopsy, at the cost of specificity (41 against 96 percent); as a triage test it would spare 27 percent of men a biopsy and find up to 18 percent more clinically significant cancers.
5-year biochemical or clinical failure-free survival 90.
15-year prostate-cancer mortality 3.
Five-year disease-free survival 86.
A milestone in how this cancer is treated.